Finlàndia - finès - Fimea (Suomen lääkevirasto)

stada arzneimittel ag - rivaroxaban - kapseli, kova - 15 mg + 20 mg - rivaroksabaani

Unió Europea - finès - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroksabaani - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitromboottiset aineet - laskimotromboembolian (vte) ehkäisy aikuisilla potilailla, jotka saavat elektiivisen lonkan tai polven korvaavan leikkauksen. hoito syvä laskimotukos (dvt) ja keuhkoembolian (pe), ja toistuvien dvt ja pe aikuisilla. (see section 4. 4 for haemodynamically unstable pe patients. hoito syvä laskimotukos (dvt) ja keuhkoembolian (pe), ja toistuvien dvt ja pe aikuisilla. (see section 4. 4 hemodynaamisesti epävakaa pe potilaat). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. hoito syvä laskimotukos (dvt) ja keuhkoembolian (pe), ja toistuvien dvt ja pe aikuisilla. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 ja 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. hoito syvä laskimotukos (dvt) ja keuhkoembolian (pe), ja toistuvien dvt ja pe aikuisilla. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Finlàndia - finès - Fimea (Suomen lääkevirasto)

avansor pharma oy - rivaroxaban - tabletti, kalvopäällysteinen - 10 mg - rivaroksabaani

Finlàndia - finès - Fimea (Suomen lääkevirasto)

reddy holding gmbh - rivaroxaban - tabletti, kalvopäällysteinen - 20 mg - rivaroksabaani

Finlàndia - finès - Fimea (Suomen lääkevirasto)

reddy holding gmbh - rivaroxaban - tabletti, kalvopäällysteinen - 15 mg - rivaroksabaani

Finlàndia - finès - Fimea (Suomen lääkevirasto)

reddy holding gmbh - rivaroxaban - tabletti, kalvopäällysteinen - 10 mg - rivaroksabaani

Finlàndia - finès - Fimea (Suomen lääkevirasto)

reddy holding gmbh - rivaroxaban - tabletti, kalvopäällysteinen - 2.5 mg - rivaroksabaani

Finlàndia - finès - Fimea (Suomen lääkevirasto)

sandoz a/s - rivaroxaban - tabletti, kalvopäällysteinen - 10 mg - rivaroksabaani

Finlàndia - finès - Fimea (Suomen lääkevirasto)

sandoz a/s - rivaroxaban - tabletti, kalvopäällysteinen - 15 mg - rivaroksabaani

Finlàndia - finès - Fimea (Suomen lääkevirasto)

sandoz a/s - rivaroxaban - tabletti, kalvopäällysteinen - 20 mg - rivaroksabaani